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A B S T R A C T
Euglycemic diabetic ketoacidosis is a post market warning in patients with type 1 diabetes and type 2
diabetes treated with SGLT-2 inhibitors. We report a case of a 39-year-old obese female with presumed
type 2 diabetes for seven years who presented to the emergency department with three days of nausea,
vomiting, and abdominal pain. Due to previous total non-adherence with a prescribed insulin regimen,
she was recently started on canagliﬂozin and liraglutide. The diagnosis of euDKA was missed in the initial
evaluation as the blood glucose level was only 167 mg/dL. Further work up showed severe metabolic ac-
idosis with an anion gap of 25 and positive ketones in the urine. She was treated successfully with dextrose
water 5%/half normal saline and an insulin drip. As part of the work up, she tested positive for glutamic
acid decarboxylase autoantibodies.
Given the increasing utilization of SGLT-2 inhibitors and the fact that patients can present with near-
normal glycemia, the diagnosis can be missed. Vigilance with the use of SGLT-2 inhibitors is necessary
to decrease morbidity and potentially mortality particularly in patients with long-standing type 2 dia-
betes associated with marked β-cell insuﬃciency, type 1 diabetes mellitus, or latent autoimmune diabetes
of adult onset.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The increased risk of euglycemic diabetic ketoacidosis (euDKA)
with sodium-glucose cotransporter 2 (SGLT-2) inhibitors is a post
market warning that Food and Drug Administration (FDA) re-
cently issued for patients with type 1 diabetes (T1DM) and type 2
diabetes (T2DM) using this new class of drugs [1]. The drugs are
only approved for use in patients with T2DM. The diagnosis of euDKA
can be diﬃcult to make, and it can go unrecognized. We present
an illustrative case of euDKA with SGLT-2 inhibitor and discuss the
possible pathophysiology of the mechanism and how it can be
predicted.
Case presentation
A 39-year-old Caucasian female with a history of gestational di-
abetes that had progressed into over diabetes mellitus seven years
prior, obesity (BMI of 30) and hypothyroidism, presented to the emer-
gency department with a three-day history of worsening nausea,
vomiting, anorexia, abdominal pain, and myalgias. After the diag-
nosis with T2DM several years ago, she did not tolerate metformin
andwas switched tomultiple doses of insulin, a regimenwith which
she was never adherent to. In fact, she admitted she was com-
pletely non-adherent to any diabetes medication for the past several
years. She recently resumed active diabetes care with a new en-
docrinologist who initiated therapywith canagliﬂozin and liraglutide
in an effort to improve medications compliance, promote weight
loss, and obtain better control of glucose levels. After initiation of
this regimen, blood glucose readings improved to around 140 mg/
dL (from a reported baseline of 300–400 mg/dL).
She denied history of recent alcohol use, starvation, or illness.
Her temperature was 97.7 F, blood pressure was 120/80mmHg, heart
rate was 133 beats per minute, and oxygen saturation was 97% on
room air; she appeared as an ill, middle-aged, obese female in mild
discomfort, with dry mucus membranes, and a diffusely tender
abdomen without guarding. Her initial chemistry was remarkable
for severe metabolic acidosis (Table 1) with a calculated anion gap
of 25. Arterial blood gas had a pH of 7.08, partial pressure of carbon
dioxide of 22mmHg, and bicarbonate of 6.5mmol/L. Lactic acid was
1.4 mmol/L, blood glucose was 167 mg/dL, sodium 142 mmol/L,
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chloride 108 mmol/L, potassium 4.5 mmol/L, urea nitrogen 18 mg/
dL, and creatinine 0.8 mg/dL.
Urine drug screen, ethanol level, acetaminophen and aspirin levels
were unremarkable. The patient’s symptoms initially did not improve
with administration of intravenous ﬂuids and antiemetic agents.
Given the unimpressive blood glucose level, the diagnosis of DKA
went unrecognized for the ﬁrst eight hours. As other causes for
anion-gap metabolic acidosis were ruled out and the urine tested
positive for ketones of 160 mg/dL, the decision was made to admit
the patient to the intensive care unit and start dextrose water 5%
with half normal saline and a regular insulin drip as per hospital-
wide DKA protocol. The euDKA resolved in 24 hours, and she
regained her appetite and was switched to a basal and pre-prandial
insulin regimen. Glutamic Acid Decarboxylase (GAD65) autoanti-
bodies test was found positive at 24.1 IU/mL, while islet cell and
insulin antibodies were negative. Hemoglobin A1c was 12%.
Discussion
EuDKA is a rare form of diabetic ketoacidosis (DKA) and is deﬁned
as DKA without marked hyperglycemia in T1DM. DKA is classical-
ly deﬁned by the triad of hyperglycemia >250 mg/dL, anion-gap
acidosis, and increased plasma ketones [2]; it is most likely to happen
in patients with T1DM, and is less likely in patient with T2DM, unless
the individual is subjected to extreme physical stress such as in-
fection or surgery. EuDKA is believed to be due to multiple factors
including low carbohydrate intake, alcohol use, and inhibition of
gluconeogenesis [2–4]. There have been cases of euDKA reported
in pregnancy, starvation and acute pancreatitis [5,6].
SGLT-2 inhibitors are one of the newest classes of
antihyperglycemicmedications approved for the treatment of T2DM.
These drugs inhibit glucose reabsorption in the proximal renal tubule,
promote glycosuria, decrease plasma glucose, and cause weight loss
[7]. Off-label use of SGLT-2 inhibitors in the setting of T1DM is in-
creasing [8,9], presumably due to the increase of obesity in those
patients.
There have been more than 70 cases of euDKA with the use of
SGLT2 inhibitors reported to the FDA since the release of the novel
class of drug in the market in 2013 [1]. Cases of euDKA have been
identiﬁed in patients treated with canagliﬂozin, dapagliﬂozin,
ipragliﬂozin, tofogliﬂozin, luseogliﬂozin, and empagliﬂozin [3].
The hypothetical mechanisms by which SGLT-2 inhibitors induce
euDKA differ in both T1DM and T2DM. SGLT-2 inhibitors induce a
rapid increase in urinary glucose excretion, ranging from 50 to 100 g/
day [10,11]. In a typical T2DM patient who consumes 50% of daily
calories as carbohydrate, this glucose loss amounts to 17–44% of the
estimated carbohydrate intake. This number can be higher in some
ethnic groups like African Americans [12]. There is a decrease in
plasma glucose levels by 20–25mg/dL, both in the overnight fasting
state and following a meal [13]. As glucose levels decrease, there
is less of a stimulus for insulin release, so plasma insulin levels fall
(by 10 pmol/L fasting and; 60 pmol/L postmeal). In contrast, plasma
glucagon concentrations increase signiﬁcantly by two mecha-
nisms: partly due to diminished paracrine inhibition by insulin, and
also because of decreased SGLT2-mediated glucose transport into
α-cells. A recent study reported that SGLT-2 is expressed on pan-
creatic α cells and that this transporter appears to function as part
of the cells glucose sensor mechanism, exposing human islets to
dapagliﬂozin-stimulated glucagon secretion [10,14]. In cases of T1DM
or latent autoimmune diabetes of adult onset (LADA), when start-
ing SGLT-2 inhibitors, clinicians or patients often decrease the dose
of insulin administered to minimize the risk of hypoglycemia [9].
This results in a decrease in circulating insulin levels, which leads
to an increase in lipolysis in adipose tissue and ketogenesis in the
liver, and more circulating ketones in the body.
Ketoacidosis has the same pathophysiology in euDKA as in DKA,
except that renal glucose clearance is twice as large with euDKA
and SGLT2 inhibitor (high level of glycosuria compared to normal
to low blood glucose) than with DKA [11,13].
Thus, in SGLT-2 inhibitor-treated T2DM patients, the lower
insulin-to-glucagon ratio stimulates lipolysis and enhances lipid ox-
idation at the expense of carbohydrate oxidation. In the face of lower
glucose concentrations, nonoxidative glucose disposal decreases,
causing less glycogen synthesis (inhibit gluconeogenesis) and lactate
release. The increased free fatty acid delivery to the liver results in
stimulation of ketogenesis, and a paradoxically twofold rise in
β-hydroxybutyrate levels [15].
Not all patients treated with SGLT-2 inhibitors will eventually
develop euDKA. Erondu et al. reported that the incidence of euDKA
with canagliﬂozin in patients with T2DM is similar to the general
population. Most reported cases had other concomitant factors that
triggered DKA, most commonly insulin reduction, low caloric and
ﬂuid intake, concurrent illness, prolonged starvation, alcohol use,
and organic pancreatic insuﬃciency [2,6,10]. Six out of twelve cases
of euDKA with canagliﬂozin reported by Erondu et al. were found
to have LADA, tested positive for GAD65 autoantibodies, or had T1DM
[7].
Our patient was diagnosed with T2DM several years prior to ad-
mission based on clinical background and obesity; however, she was
non adherent to prescribed insulin regimenwhich she stopped before
her endocrinologist started her on an SGLT-2 inhibitor. She certain-
ly met diagnostic criteria of DKA, save for the relatively unimpressive
blood glucose level since the lactate level was normal, and she had
no history of starvation or alcohol consumption. She was tested pos-
itive for GAD65 autoantibodies and was diagnosed with LADAwhich
placed her at high risk of developing euDKA in context of recent
use of SGLT-2 inhibitor. What is remarkable (and perhaps
counterintuitive) is the fact that her blood sugar improved with ini-
tiation of pharmacotherapy, owing perhaps to the above-mentioned
mechanisms in a patient misdiagnosed as having T2DM, when in
fact she had LADA.
Indeed,most patients andmany clinicians fail to recognize euDKA,
due to an acceptable level of blood glucose, leading to unneces-
sary testing and/or decrease of insulin dose [15]. All cases of euDKA
responded to intravenous ﬂuid with dextrose water 5% with half
normal saline and a regular insulin drip [2]. EuDKA can be de-
tected and easily prevented. Patients undergoing treatment with
SGLT-2 inhibitors should be educated about the risk of euDKA. They
should be encouraged to maintain vigorous ﬂuid intake and to
consume carbohydrates if they experience symptoms of nausea,
vomiting or even malaise (symptoms of ketonuria/ketonemia) es-
pecially after alcohol intake, recent decrease in insulin dose, or
Table 1
Pertinent data
Day 1 Day 1 Day 2 Day 2 Day 2 Day 2
1300 2200 0100 0600 0900 1200
Blood glucose mg/dL 167 175 138 169 114 170
Bicarbonate mmol/L 9 10 12 18 18 19
Calculated anion gap (normal 8 to 12) 25 18 18 13 14 10
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current illness. Patients in this situation should stop SGLT-2 inhib-
itor and contact their doctors [1,15].
Conclusion
Recently, the FDA has been increasing awareness of potential
euDKA caused by SGLT-2 inhibitors. However, physicians and pa-
tients still need to be made aware that such risk may be increased
in long-standing T2DM patients with marked β-cell insuﬃciency
or LADA with rapid evolution toward overt T1DM.
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